A Study of Virtual Reality and Linaclotide for IBS-C
Mayo Clinic · Irritable Bowel Syndrome With Constipation
Not applicable
Recruiting
65
2026-07
Evidence dashboardStudies since 2006Updated Jul 31, 2026
LinaclotideClinical Trials.
A source-linked view of every Linaclotide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 59
- Recruiting
- 3
- Completed
- 41
- Terminated
- 4
- Results posted
- 24
- Average enrollment
- 394
- Countries
- 23
- Highest phase
- Phase 4
Largest indexed study
3,028 participants · NCT04462900 →Developer / research origin
Ironwood Pharmaceuticals
Evidence summary
Activity is not efficacy.
Linaclotide appears in 59 indexed studies: 3 recruiting, 41 completed and 24 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Linaclotide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Colorectal Adenoma · Stage 0 Colorectal Cancer AJCC v8
Phase 2
Active, not recruiting
150
2026-07
Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis
University of Nottingham · Cystic Fibrosis (CF)
Early Phase 1
Recruiting
26
2026-05
Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation
Texas Tech University Health Sciences Center, El Paso · Chronic Constipation · Diabete Mellitus
Phase 4
Active, not recruiting
23
2026-04
"Efficacy and Safety of Linaclotide in Chronic Constipation"
Md Mehedi Shahriar · Chronic Idiopathic Constipation · Irritable Bowel Syndrome (IBS-C)
Phase 4
Not yet recruiting
90
2026-02
Linaclotide for Colonoscopy Bowel Prep
University of Florida · Patients Scheduled for Colonoscopy
Phase 1 / Phase 2
Recruiting
10
2026-01
Showing 6 of 7 studies
NCT IDStudyPhase / statusEnrollmentUpdated
A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
AbbVie · Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
Phase 3
Completed
123
2026-05
GCC Agonist Signal in the Small Intestine
University of Wisconsin, Madison · Barrett Esophagus · Gastroesophageal Reflux Disease
Phase 1
Completed
43
2026-04
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
AbbVie · Irritable Bowel Syndrome With Constipation · Functional Constipation
Phase 3
Completed
381
2026-01
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
AbbVie · Functional Constipation
Phase 2
Completed
19
2026-01
Effect to Linaclotide on Colonic Motility
Universitaire Ziekenhuizen KU Leuven · Chronic Constipation
Phase 4
Completed
10
2025-05
Clinical Study of Bowel Preparation Before Colonoscopy
Jinling Hospital, China · Bowel Preparation
Not applicable
Completed
444
2024-12
Showing 6 of 41 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Assessment of Responsiveness to Treatment by Experience Sampling Method
Maastricht University Medical Center · Constipation-predominant Irritable Bowel Syndrome
Not applicable
Terminated
16
2022-05
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
Ironwood Pharmaceuticals, Inc. · Irritable Bowel Syndrome Characterized by Constipation
Phase 4
Terminated
20
2021-12
HygiRelief Procedure and HygiSample Evaluation for Functional Constipation
HyGIeaCare, Inc. · Rome IV Functional Constipation
Not applicable
Withdrawn
0
2021-09
Cognitive and Psychiatric Effects of Linaclotide on Patients With Constipation
McMaster University · Constipation · Irritable Bowel Syndrome
Not applicable
Withdrawn
0
2021-08
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
Forest Laboratories · Irritable Bowel Syndrome With Constipation
Phase 2
Terminated
101
2020-12
Efficacy of Linaclotide to Senna for CIC
TriHealth Inc. · Chronic Idiopathic Constipation
Not applicable
Terminated
9
2019-07
Full study index
Search Linaclotide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
59 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 34511390 ↗Stefano MA, Sandy NS, Zagoya C, Duckstein F, Ribeiro AF, Mainz JG, Lomazi EA. Diagnosing constipation in patients with cystic fibrosis applying ESPGHAN criteria. J Cyst Fibros. 2022 May;21(3):497-501. doi: 10.1016/j.jcf.2021.08.021. Epub 2021 Sep 9. No abstract available.Linked from NCT07569419PMID 32389617 ↗Stefano MA, Poderoso RE, Mainz JG, Ribeiro JD, Ribeiro AF, Lomazi EA. Prevalence of constipation in cystic fibrosis patients: a systematic review of observational studies. J Pediatr (Rio J). 2020 Nov-Dec;96(6):686-692. doi: 10.1016/j.jped.2020.03.004. Epub 2020 May 8.Linked from NCT07569419PMID 3748682 ↗Rubinstein S, Moss R, Lewiston N. Constipation and meconium ileus equivalent in patients with cystic fibrosis. Pediatrics. 1986 Sep;78(3):473-9.Linked from NCT07569419PMID 30118317 ↗McHugh DR, Cotton CU, Moss FJ, Vitko M, Valerio DM, Kelley TJ, Hao S, Jafri A, Drumm ML, Boron WF, Stern RC, McBennett K, Hodges CA. Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3. Am J Physiol Gastrointest Liver Physiol. 2018 Nov 1;315(5):G868-G878. doi: 10.1152/ajpgi.00261.2017. Epub 2018 Aug 17.Linked from NCT07569419PMID 20626735 ↗Marciani L, Wright J, Foley S, Hoad CL, Totman JJ, Bush D, Hartley C, Armstrong A, Manby P, Blackshaw E, Perkins AC, Gowland PA, Spiller RC. Effects of a 5-HT(3) antagonist, ondansetron, on fasting and postprandial small bowel water content assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2010 Sep;32(5):655-63. doi: 10.1111/j.1365-2036.2010.04395.x.Linked from NCT07569419PMID 25060551 ↗Marciani L, Garsed KC, Hoad CL, Fields A, Fordham I, Pritchard SE, Placidi E, Murray K, Chaddock G, Costigan C, Lam C, Jalanka-Tuovinen J, De Vos WM, Gowland PA, Spiller RC. Stimulation of colonic motility by oral PEG electrolyte bowel preparation assessed by MRI: comparison of split vs single dose. Neurogastroenterol Motil. 2014 Oct;26(10):1426-36. doi: 10.1111/nmo.12403. Epub 2014 Jul 24.Linked from NCT07569419PMID 38533975 ↗Luo M, Liu Y, Nikolovska K, Riederer B, Patrucco E, Hofmann F, Seidler U. cGMP-dependent kinase 2, Na+/H+ exchanger NHE3, and PDZ-adaptor NHERF2 co-assemble in apical membrane microdomains. Acta Physiol (Oxf). 2024 Apr;240(4):e14125. doi: 10.1111/apha.14125. Epub 2024 Mar 27.Linked from NCT07569419PMID 31428412 ↗Hayee B, Watson KL, Campbell S, Simpson A, Farrell E, Hutchings P, Macedo P, Perrin F, Whelan K, Elston C. A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders. United European Gastroenterol J. 2019 Aug;7(7):881-888. doi: 10.1177/2050640619841545.Linked from NCT07569419
Related pages
Keep researching Linaclotide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.